: Usana sees sales bump in China, but 2023 still uncertain

Usana Health Sciences Inc. falls more than 4% in the extended session Thursday after the multi-level marketing company calls for lower 2023 sales and profit than Wall Street expected, saying it is unsure whether an uptick in sales at the end of 2022 will last.